Verena Krähling

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

Till Koch, Christine Dahlke, Anahita Fathi et al. · The Lancet Infectious Diseases · 2020 · 171 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

Leonie M. Weskamm, Anahita Fathi, Matthijs P. Raadsen et al. · Cell Reports Medicine · 2022 · 28 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Anahita Fathi, Christine Dahlke, Verena Krähling et al. · Nature Communications · 2022 · 21 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial

Matthijs P. Raadsen, Christine Dahlke, Anahita Fathi et al. · The Lancet Infectious Diseases · 2024 · 18 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

Leonie Mayer, Leonie M. Weskamm, Anahita Fathi et al. · npj Vaccines · 2024 · 12 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17